MarketBeat summarized current ratings and price targets for Arcturus Therapeutics.
1 report, 1 independent
Updated Sep 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat summarized current ratings and price targets for Arcturus Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arcturus Therapeutics
biotech company
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.
- MarketBeat reported the consensus rating for Diaceutics PLC.
- MarketBeat released new recommendations and comparisons for ArcelorMittal and Lifezone Metals.
- MarketBeat provided recent stock ratings for the company Phibro.
- TD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.